OpenAlex
PricingAboutJobs
Log inGet started
Work

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

HTML

Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: European Journal of Cancer
DOI: 10.1016/j.ejca.2013.04.002
Authors: Philippe Rougier, Hanno Riess, Robert Manges, Petr Karasek, Yves Humblet, Carlo Barone, Armando Santoro, Sylvie Assadourian, Laurence Hatteville, Philip A. Philip
Institutions: Hôpital Européen Georges-Pompidou, Charité – Universitätsmedizin Berlin, Masaryk Memorial Cancer Institute, Cliniques Universitaires Saint-Luc, Agostino Gemelli University Polyclinic, Sanofi (France), The Barbara Ann Karmanos Cancer Institute
Language: English

Topic: Pancreatic and Hepatic Oncology Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: aflibercept, gemcitabine, metastatic pancreatic cancer, first-line therapy, anti-VEGF therapy, overall survival, progression-free survival, futility, adverse events
SDG: Good health and well-being

Open Access status: closed

Funder: Sanofi
OpenAlex ID: W1976156924
FWCI: 10.21
Cites: 33
Cited by: 205
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms